Clinical Trials

MAA-202

We are currently enrolling the Phase 1/2 study, MAA-202, for those living with Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitors on emicizimab prophylaxis

If you’re interested in participating in this study, please click below for additional information:

For individuals

For physicians

This study is designed to evaluate the safety and effectiveness of a study medication for treatment of bleeding episodes in patients 12 or older with Factor VII deficiency (FVIID), Glanzmann Thrombasthenia (GT), or Hemophilia A with inhibitor patients receiving Hemlibra® (emicizumab) prophylaxis (HAwI-E).

The study drug, known as “MarzAA” is being developed to treat and control bleeding events experienced by individuals with bleeding disorders such as FVIID, GT or HAwI-E. It is administered using a needle placed just under the skin and can be taken at home.

For more information on the MAA-202 study, including study locations, please see the information listed on the ClinicalTrials.gov website.

To review the MarzAA-related scientific publications, presentations, and posters, click here.

For individuals living with Hemophilia

If you have bleeding episodes caused by FVII deficiency, Glanzmann Thrombasthenia, or Hemophilia A with inhibitors, you may want to learn more about the MAA-202 study.

For more information, please contact Catalyst Biosciences at 202-General@catbio.com.

For physicians

If you are a physician and have a patient who has bleeding episodes caused by FVII deficiency, Glanzmann Thrombasthenia, and Hemophilia A you may want to learn more about the MarzAA 202 study.

For more information, please contact Catalyst Biosciences at 202-General@catbio.com.

X